miR-429 Suppresses Endometrial Cancer Progression and Drug Resistance via DDX53.
J Pers Med
; 13(9)2023 Aug 25.
Article
em En
| MEDLINE
| ID: mdl-37763070
ABSTRACT
(1) Background:
To examine miR-429-meditated DEAD (Asp-Glu-Ala-Asp) box polypeptide 53 (DDX53) function in endometrial cancer (EC). (2)Methods:
DDX53 and miR-429 levels were measured using quantitative real-time polymerase chain reaction and western blotting assays, cell invasion and migration using Transwell invasion and wound healing assays, and cell proliferation using colony-forming/proliferation assays. A murine xenograft model was also generated to examine miR-429 and DDX53 functions in vivo. (3)Results:
DDX53 overexpression (OE) promoted key cancer phenotypes (proliferation, migration, and invasion) in EC, while in vivo, DDX53 OE hindered tumor growth in the murine xenograft model. Moreover, miR-429 was identified as a novel miRNA-targeting DDX53, which suppressed EC proliferation and invasion. (4)Conclusions:
DDX53 and miR-429 regulatory mechanisms could provide novel molecular therapies for EC.
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Idioma:
En
Revista:
J Pers Med
Ano de publicação:
2023
Tipo de documento:
Article